Exelixis Inc. (EX9)
FSX
Closed
Oct 6, 2026
Day's Range
52.0152 wk Range
29.41Overview - EX9 - Exelixis Inc.
Key Statistics
Valuation
Enterprise Value
10.75B
P/E (Trailing)
‪19.33‬
P/E (Forward)
‪59.78‬
PEG Ratio
‪0.77‬
Price / Sales (TTM)
‪5.29‬
Price / Book
‪7.90‬
EV / EBITDA
‪11.87‬
Profitability
Gross Margin
‪96.71%‬
Profit Margin
‪35.33%‬
Operating Margin
‪39.51%‬
Return on Assets
‪23.97%‬
Return on Equity
‪44.39%‬
Ownership
Shares Outstanding
248.88M
Float
213.60M
Held by Insiders
‪1.84%‬
Held by Institutions
‪106.76%‬
Price stats
Beta
‪0.46‬
50-Day Avg
‪48.18‬
200-Day Avg
‪42.17‬
Dividends
Payout Ratio
‪0.00%‬
Market Cap - EX9 - Exelixis Inc.
Peers - EX9 - Exelixis Inc.
Peer Comparison
Compared with companies in Biotechnology listed on FSX.
- EX9FSXExelixis Inc.12.88BMarket Cap+34.30%52-week change19.33P/E (Trailing)‪35.33%‬Profit Margin
- ANLFSXAnalog Devices Inc.179.11BMarket Cap+43.92%52-week change47.10P/E (Trailing)‪29.78%‬Profit Margin
- 0QFFSXModerna Inc.69.12BMarket Cap+87.76%52-week change25.27P/E (Trailing)‪-141.42%‬Profit Margin
- 64BFSXAstera Labs, Inc.53.43BMarket Cap+42.53%52-week change179.66P/E (Trailing)‪30.74%‬Profit Margin
- 1AEFSXargenx SE52.63BMarket Cap+28.29%52-week change36.62P/E (Trailing)‪32.26%‬Profit Margin
- 1AEAFSXargenx SE American Depositary Receipt50.36BMarket Cap+25.47%52-week change34.88P/E (Trailing)‪32.26%‬Profit Margin
- 42ZFSXRevolution Medicines, Inc.37.58BMarket Cap+78.78%52-week change-29.47P/E (Trailing)‪0.00%‬Profit Margin
Profile Summary - EX9 - Exelixis Inc.
About
Exelixis Inc. is an oncology-focused biopharmaceutical company that discovers, develops, and commercializes medicines for difficult-to-treat cancers. The company’s current portfolio centers on cancer therapies built around cabozantinib, including CABOMETYX and COMETRIQ, which are used across multiple tumor types in…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
